Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$8.01 - $12.84 $1.09 Million - $1.75 Million
-136,557 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$11.94 - $16.09 $927,117 - $1.25 Million
-77,648 Reduced 36.25%
136,557 $1.72 Million
Q2 2021

Aug 17, 2021

SELL
$14.36 - $20.93 $1.9 Million - $2.77 Million
-132,325 Reduced 38.19%
214,205 $3.31 Million
Q1 2021

May 18, 2021

BUY
$18.19 - $33.25 $5.02 Million - $9.18 Million
276,230 Added 392.93%
346,530 $7 Million
Q4 2020

Feb 12, 2021

BUY
$15.87 - $31.64 $1.12 Million - $2.22 Million
70,300 New
70,300 $1.9 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $82.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.